Helliwell Philip S
Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK.
J Rheumatol. 2006 Jul;33(7):1439-41. Epub 2006 May 15.
Dactylitis is a hallmark clinical feature of psoriatic arthritis (PsA). Acute dactylitis appears to be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory rheumatic drugs and local corticosteroid injections to treat dactylitis, although conventional disease modifying antirheumatic drugs also are recommended. In this systematic review, the limited data on treatments for dactylitis in PsA highlight the need for a valid, reliable, and responsive clinical outcome measure. Infliximab is the only drug to demonstrate significant improvement of dactylitis during a clinical study.
指(趾)炎是银屑病关节炎(PsA)的标志性临床特征。急性指(趾)炎似乎是PsA和银屑病的严重程度标志物。传统上,临床医生使用非甾体类抗炎风湿药物和局部皮质类固醇注射来治疗指(趾)炎,尽管也推荐使用传统的改善病情抗风湿药物。在这项系统评价中,关于PsA中指(趾)炎治疗的有限数据凸显了对一种有效、可靠且灵敏的临床结局指标的需求。英夫利昔单抗是唯一一种在临床研究中显示能显著改善指(趾)炎的药物。